



# Rabbit Anti-Bevacizumab polyclonal antibody (CABT-ZB262)

This product is for research use only and is not intended for diagnostic use.

## PRODUCT INFORMATION

<b>Product Overview</b>	CABT-ZB262 is produced from sera of a rabbit immunized with Bevacizumab.
<b>Specificity</b>	The product is specific for Bevacizumab.
<b>Target</b>	Bevacizumab
<b>Immunogen</b>	Bevacizumab
<b>Isotype</b>	IgG
<b>Source/Host</b>	Rabbit
<b>Purification</b>	Affinity purification
<b>Conjugate</b>	Unconjugated
<b>Applications</b>	<p>Suitable for use in pharmacokinetic (PK) assay. Other applications have not been tested but use in such assays should not necessarily be excluded.</p> <p>This antibody serves as an excellent positive control for Bevacizumab immunogenicity (ADA) assays.</p> <p>Recommended Working Concentration: 0.05-0.2 µg/ml</p>
<b>Reconstitution</b>	Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
<b>Format</b>	Purified, Lyophilized.
<b>Size</b>	40 µg
<b>Buffer</b>	Lyophilized with PBS, pH 7.4, contains 0.02% sodium azide.

<b>Preservative</b>	0.02% sodium azide
<b>Storage</b>	The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid freeze/thaw cycles.
<b>Ship</b>	Wet ice

## BACKGROUND

<b>Introduction</b>	Bevacizumab (Avastin) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with colon cancer, lung cancer, glioblastoma, renal-cell carcinoma, and age-related macular degeneration. As angiogenesis inhibitor, Bevacizumab blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).
<b>Keywords</b>	Rabbit polyclonal antibody to Avastin; Bevacizumab; Avastin; Anti-V-EGFA antibody

## GENE INFORMATION

<b>Synonyms</b>	Rabbit polyclonal antibody to Avastin; Bevacizumab; Avastin; Anti-V-EGFA antibody
-----------------	---